The vast majority of people with MS receive an initial diagnosis of the relapsing-remitting (RR) form of the disease ...

The latest research on therapeutic management of patients with relapsing-remitting multiple sclerosis (MS) presented at the European Committee for Treatment and Research in Multiple Sclerosis 2024 ...

Leptomeningeal inflammation in a mouse model of multiple sclerosis triggers deeply penetrating gene changes in underlying brain tissue, described using spatial transcriptomics.

Suicide ideation is relatively common among patients newly diagnosed with multiple sclerosis, regardless of depression ...

Columnist Desiree Lama says she's appreciating life, because her MS symptoms and progression aren't a major concern at the ...

Living with relapsing-remitting multiple sclerosis? Get answers to common questions and tips to help you talk to your doctor about it.

In relapsing-remitting multiple sclerosis (MS), all of the currently available disease-modifying medications are injectables marketed for self-injection. Problems with self-injection pose a ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

Around 8 out of 10 people with MS will have the relapsing remitting type of MS, according to the NHS. Relapsing–remitting multiple sclerosis is a chronic, disabling, neurological condition that ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key ...

NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term ...